EmbryoGlue® gives hope to infertile couples

In a study presented at the on-going ESHRE conference in Istanbul, Vitrolife’s
patent protected medium EmbryoGlue® has once again been proven to increase both
implantation and pregnancy rates, regardless of hormone stimulation of the
endometrium or not.
Dr. Nakagawa from Japan, who performed the study, investigated whether the
preparation method of the endometrium, the lining of the uterus, before transfer
had an effect on pregnancy rate or not. The prospective randomized study
included 203 patients under the age of 40, all with four or more previous
implantation failures. 101 of the women had embryo transfer in a natural
ovulation cycle, and 102 women were prepared by hormone replacement cycle.
Patients in each group were allocated to transfer with either EmbryoGlue® or a
transfer medium with no hyaluronan.

The study showed that the pregnancy rate increased significantly for the group
receiving transfer in EmbryoGlue®. In the group with natural cycles it increased
from 10% till 31.4% and in the group receiving transfer in a hormone stimulated
cycle from 15.7% to 41.2%

”I am very happy to present these data, showing that women with many previous
implantation failures have a chance of becoming parents,” says Dr. Nakagawa.

EmbryoGlue® is a medium patent protected by Vitrolife, enriched with hyaluronan,
a natural substance abundant in all tissues in the body. It has a unique
combination of a high concentration of hyaluronan and recombinant albumin.
EmbryoGlue® is used when transferring embryos into the woman as the final step
of an IVF treatment.

The use of EmbryoGlue® for embryo transfer has been analysed in numerous
studies, showing an increased treatment success independent of patient age, day
of transfer and now also preparation of the endometrium.

July 4, 2012

Gothenburg, Sweden
VITROLIFE AB (publ)
Thomas Axelsson
CEO
Queries should be addressed to:

Thomas Axelsson, CEO, phone +46 31 721 80 01

Mikael Engblom, CFO, phone +46 31 721 80 14

Vitrolife is required to publish the information in this press release in
accordance with the Swedish Securities Market Act and/or the Financial
Instruments Trading Act. The information was submitted for publication on July
4, 2012 at 08.30 a.m.

This is a translation of the Swedish version of the press release. When in
doubt, the Swedish wording prevails.
Vitrolife (http://www.vitrolife.com/en/Corporate/) is a global
biotechnology/medical device Group that works in the areas of Fertility and
Transplantation. The Fertility (http://www.vitrolife.com/en/Fertility/) product
area works with nutrient solutions (media), cryopreservation products and
advanced consumable instruments such as needles and pipettes, for the treatment
of human infertility. Work is also carried out to enable the use and handling of
stem cells for therapeutic purposes. The
Transplantation (http://www.xvivoperfusion.com/transplantation/) product area
works with solutions and systems for assessing and preserving organs outside the
body, so as to be able to select usable organs and keep them in optimal
condition pending transplantation.

Vitrolife (http://www.vitrolife.com/en/Corporate/) today has approximately 220
employees and its products are sold in almost 90 markets. The company is
headquartered in Gothenburg, Sweden, and there are also offices in USA,
Australia, France, Italy, United Kingdom, China and Japan. The Vitrolife
share (http://www.vitrolife.com/en/Corporate/Financial/The-share1/) is listed on
NASDAQ OMX
Stockholm (http://www.nasdaqomxnordic.com/aktier/shareinformation?Instrument=SSE
1 
3469), Small Cap.

________________________________________________________________________________
_ 
________________________________

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity
number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail:
info@vitrolife.com. Website: www.vitrolife.com/